Table 4 Results of separate DOAC vs. VKA

VKA

Dabigatran

Stroke

26.77

45.94

1.93 (1.82–2.03)

< .001

TIA

11.64

14.13

1.33 (1.22–1.45)

< .001

Embolism (systemic)

3.69

3.07

0.93 (0.79–1.10)

.42

Bleeding

134.82

107.77

0.85 (0.83–0.88)

< .001

Mortality (all cause)

52.34

63.49

–

–

VKA

Rivaroxaban

Stroke

25.88

27.77

1.13 (1.10–1.17)

< .001

TIA

10.69

10.83

1.06 (1.01–1.11)

.02

Embolism (systemic)

3.79

2.99

0.83 (0.77–0.90)

< .001

Bleeding

135.19

133.23

1.03 (1.01–1.04)

< .001

Mortality (all cause)

57.79

75.02

–

–

VKA

Apixaban

Stroke

27.58

38.81

1.52 (1.46–1.58)

< .001

TIA

11.58

12.33

1.15 (1.08–1.22)

< .001

Embolism (systemic)

3.77

2.75

0.75 (0.67–0.85)

< .001

Bleeding

137.8

93.36

0.71 (0.70–0.73)

< .001

Mortality (all cause)

64.26

74.45

–

–

VKA

Edoxaban

Stroke

26.24

15.53

0.88 (0.74–1.05)

.16

TIA

11.18

5.18

0.71 (0.53–0.95)

.02

Embolism (systemic)

3.94

1.31

0.29 (0.17–0.51)

< .001

Bleeding

133.92

69.82

0.74 (0.68–0.81)

< .001

Mortality (all cause)

53.58

30.62

–

–